A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

Exclusion Criteria

• •Uncontrolled, clinically significant disease which in the opinion of the Principal Investigator and Sponsor (MDTx) would place the subject at risk through study participation or would confound the assessment of the safety of MDT-637
• •Evidence of current or history of respiratory disease; for instance asthma, emphysema, chronic bronchitis or cystic fibrosis.
• •Upper respiratory tract infection within 6 weeks of Visit 1
• •Symptoms of rhinitis (stuffy nose, rhinorrhea, sneezing, nasal discharge) within 2 weeks of Visit 1
• •Current symptoms of cough, dyspnea, wheezing or nocturnal awakenings due to respiratory symptoms
• •History of significant nasal irritation from nasal inhalation of medication
• •History of malignancy
• •History of clinically significant alcohol or drug abuse
• •Positive drug screen for drugs of abuse
• •Positive test for HIV, Hepatitis B or Hepatitis C
• •Allergy to lactose, or lactose intolerance
• •Use of prescription medication within 14 days of Visit 2 or over-the-counter preparations, including dietary and herbal supplements, within 5 days of Visit 2
• •Positive urine pregnancy test at Visit 1
• •Inability to perform reproducible spirometry in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
• •Abnormal QTc interval at Visit 1(\>450 msec in males or \> 470 msec in females)
• •Significant blood donation (or testing) in previous 8 weeks